Page 72 - நோர்வே நிறுவனம் ஆஃப் பொது ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Oxford-AstraZeneca COVID-19 vaccine is fast becoming a subject of notoriety. First, will States obtain it? Second, will they use it? The first answer has generally been affirmative, given the vaccine s ease of storage and relative cheapness. The second is becoming increasingly difficult. Orders have been made and supplies – some of them anyway - furnished, but vials and batches are not being used. Countries are either restricting or suspending the jab. AstraZeneca finds itself mounting what can only be a round-the-clock communications battle trying to dissuade officials not to put the brakes on. Various artillery pieces have been marshalled against it. In late January, French President Emmanuel Macron expressed disappointment with the vaccine a mere few hours before the European Medicines Agency (EMA) approved its use on all adults. The real problem on AstraZeneca is that it doesn t work the way we were expecting it to, he told press members. We re waiting for the EMA resu

South africaBaden wubergSouth africanGregor waschinskiMarkus lehmkuhlZweli mkhizeThomas mertensEuropean medicines agencySweden public health agencyNorwegian institute of public healthKarlsruhe institute of technologyGerman standing committee on vaccinationFrench president emmanuel macronKarlsruhe instituteGerman standing committeePublic health agency